Better Together: Targeted Combination Therapies in Breast Cancer
Elisa Zanardi1, Giacomo Bregni1, Filippo de Braud1
1Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Abstract:
Recent discoveries both in cell proliferation and survival mechanisms and new antineoplastic agents have led to deep change in the breast cancer treatment paradigm. Nonetheless, all of the progress in knowledge and strategy has not been enough to overcome mechanisms of escape and resistance put in place by the tumor cells. New targeted agents mean new possibilities for combinations, a viable option to try to stop compensatory pathways of tumor growth activated in response to therapeutics. The main challenges in designing a combined therapy come from the variety of subtypes of breast cancer (luminal A, luminal B, HER2-enriched, and basal-like) and from the multitude of pathways each subtype can exploit. Recent research has focused on dual blockade of HER2 (trastuzumab-lapatinib; trastuzumab-pertuzumab) and concomitant blockade of the endocrine driver and other pathways such as the PI3K/AKT/mTOR pathway (everolimus-exemestane), HER2 (trastuzumab/lapatinib-endocrine therapy) and the cell cycle through cyclin-dependent kinase inhibition (letrozole-palbociclib). This combined and personalized approach to treatment needs a profound knowledge of the mechanisms leading to proliferation in each tumor subtype. Deepening our understanding of tumor growth is mandatory to keep improving the efficacy of combination therapy.
Insights
Despite advances, breast cancer treatment faces resistance. Combination therapies targeting specific pathways and subtypes offer new hope for improved treatment efficacy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Breast cancer treatment has evolved with new agents targeting cell proliferation and survival.
- Tumor cells develop resistance mechanisms, limiting the effectiveness of single-agent therapies.
- Combination therapies are emerging as a strategy to overcome resistance and enhance treatment outcomes.
Purpose of the Study:
- To explore the potential of combination therapies in overcoming breast cancer resistance.
- To highlight the challenges and opportunities in designing personalized combination treatments for diverse breast cancer subtypes.
- To emphasize the need for a deeper understanding of tumor growth mechanisms for optimizing combination strategies.
Main Methods:
- Review of recent discoveries in cell proliferation, survival mechanisms, and novel antineoplastic agents.
- Analysis of current combination therapy strategies, including dual HER2 blockade and pathway inhibition (e.g., PI3K/AKT/mTOR, cell cycle).
- Examination of treatment approaches tailored to specific breast cancer subtypes (luminal A, luminal B, HER2-enriched, basal-like).
Main Results:
- Combination therapies, such as dual HER2 blockade (trastuzumab-lapatinib, trastuzumab-pertuzumab) and pathway inhibition (everolimus-exemestane), show promise.
- Targeting the PI3K/AKT/mTOR pathway and cell cycle (letrozole-palbociclib) are key strategies in combination regimens.
- Personalized treatment requires understanding subtype-specific proliferation mechanisms.
Conclusions:
- Combination therapy represents a viable strategy to counteract tumor resistance in breast cancer.
- Effective combination treatments necessitate a comprehensive understanding of breast cancer subtypes and their unique signaling pathways.
- Continued research into tumor growth mechanisms is crucial for advancing the efficacy of personalized combination therapies.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies